XEQT vs VEQT vs ZEQT: Why XEQT Looks Like the Winner

Key Takeaways

• XEQT’s back‑test assumes constant 60% U.S. equity weighting.
• VEQT and ZEQT use dynamic regional allocations based on market caps.
• U.S. equities delivered highest returns over the past 20 years.
• Drawdown depth, not just returns, drives long‑term investor outcomes.

Pulse Analysis

The Canadian market has seen a surge in all‑equity, single‑ticker ETFs that promise a simple, diversified exposure to global stocks. XEQT (iShares), VEQT (Vanguard) and ZEQT (BMO) are the three flagship products, each bundling U.S., Canadian, European and emerging‑market equities into a single fund. Because Canadian investors lack a domestic large‑cap U.S. proxy, these ETFs have become core holdings for retirement accounts and robo‑advisors. Understanding how each fund constructs its regional mix is essential before treating them as interchangeable.

Back‑testing these portfolios often reveals XEQT edging out its peers, but the advantage stems from a single modeling assumption: a fixed U.S. equity allocation, typically around 60 percent. Over the last two decades, U.S. stocks outperformed every other region, so any model that holds that weight constant will naturally generate higher cumulative returns. VEQT and ZEQT, by contrast, rebalance their regional exposure according to market‑cap shifts, which can reduce upside in bull markets but also temper volatility during corrections. Relying solely on back‑tested totals therefore masks the true risk profile.

Investors should therefore shift focus from headline returns to drawdown depth and recovery speed. XEQT’s higher historical return comes with a steeper equity‑only drawdown, while VEQT and ZEQT tend to smooth losses through periodic reallocation toward non‑U.S. markets. For long‑term savers, the choice hinges on risk tolerance, tax considerations, and the desire for a set‑and‑forget vehicle versus a dynamically rebalanced one. Incorporating these nuances into portfolio construction can improve outcomes more than chasing the modest back‑tested edge that XEQT appears to hold.